2篇
您的检索式：作者名="Jiebing Tang"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | RP11-495P10.1 promotes HCC cell proliferation by regulating reprogramming of glucose metabolism and acetylation of the NR4A3 promoter via the PDK1/PDH axis显示文摘The incidence and related death of hepatocellular carcinoma(HcC)have increased over the past decades.However,the molecular mechanisms underlying HCC pathogenesis are not fully understood.Long noncoding RNA(lncRNA)RP11-495P10.1 has been proven to be closely associated with the progression of prostate cancer,but its role and specific mechanism in HCC are still unknown.Here,we identify that RP11-495P10.1 is highly expressed in HCC tissues and cells and contributes to the proliferation of HcC cells.Moreover,this study demonstrates that RP11-495P10.1 affects the proliferation of Hcc by negatively regulating the expression of nuclear receptor subfamily 4 group a member 3(NR4A3).Glycometabolism reprogramming is one of the main characteristics of tumor cells.In this study,we discover that RP11-495P10.1 regulates glycometabolism reprogramming by changing the expression of pyruvate dehydrogenase kinase 1(PDK1)and pyruvate dehydrogenase(PDH),thus contributing to the pro-liferation of HCC cells.Furthermore,knockdown of RP11-495P10.1 increases enrichment of H3K27Ac in the pro-moter of NR4A3 by promoting the activity of PDH and the production of acetyl-CoA,which leads to the increased transcription of NR4A3.Altogether,RP11-495P10.1 promotes HCC cell proliferation by regulating the reprogram-ming of glucose metabolism and acetylation of the NR4A3 promoter via the PDK1/PDH axis,which provides an IncRNA-oriented therapeutic strategy for the diagnosis and treatment of HCC. | Chi Liu Jie Shi Zhengyuan Jiang Shan Jiang Yuan Wu Dongqian Peng Jiebing Tang Linchi Guo | 2024 | Acta Biochimica et Biophysica Sinica2024，56，1： | 0 |
| 2 | Advances and prospects of drug clinical research in colorectal cancer in 2022显示文摘Colorectal cancer(CRC)is the third most common cancer and the second leading cause of cancer death worldwide.Clinical research results have provided more treatment opportunities for CRC patients,showing that an optimal combination of existing drugs and new drugs is needed to mitigate the burden of this disease.In this review,we have summarized recent advances in drug clinical research for CRC in 2022,including chemotherapy,targeted therapy,and immunotherapy,to find opportunities for substantial improvements in drug discovery and clinical development methods. | Dan Su Chao Liu Jie Cui Jiebing Tang Yuli Ruan Yanqiao Zhang | 2023 | Cancer Innovation2023，2，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员